Results 261 to 270 of about 4,815,078 (315)

Elicited Repetitive Daily Blindness Associated With Gain-of-Function <i>SCN1A</i> Variants and Responsiveness to Sodium Channel Blockers. [PDF]

Neurol Genet
Cestèle S, Harper AJ, Marra S, Leroudier N, Rusconi R, Dhifallah S, Horrocks IA, Kirkham FJ, Morgan IMR, Singh J, Stobo DJ, Symonds JD, Zuberi SM, Mantegazza M, Brunklaus A.   +14 more
europepmc   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Temporal point process modeling of aggressive behavior onset in psychiatric inpatient youths with autism. [PDF]

Sci Rep
Potter M, Everett M, Singh A, Stratis G, Watanabe Y, Demirkaya A, Erdogmus D, Imbiriba T, Goodwin MS.   +8 more
europepmc   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Multiomics profiling of zebrafish embryonic cell line PAC2 across growth phases to assess its relevance for toxicological studies. [PDF]

PLoS One
Degeratu MO, Bertoli J, Huwa N, Lopez Rodriguez D, Revel M, Schönenberger R, Vom Berg C, Schirmer K, Groh KJ.   +8 more
europepmc   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Applications of likelihood-based methods for the reliability parameter of the location and scale exponential distribution. [PDF]

Bar-Lev, S.K., Duyn Schouten, F.A. van der   +1 more
core   +1 more source

A Twist in Electronic Relaxation of Pyrimidine Nucleosides and Nucleotides: Impact of C5 Methylation on Nonadiabatic Transition and Photohydration Damage. [PDF]

J Am Chem Soc
Ghosh S, Obara Y, Jaiswal VK, Taddei M, Nenov A, Conti I, Garavelli M, Suzuki T.   +7 more
europepmc   +1 more source

Determinants of Protein Folding Pathways: Lessons from Metamorphic Proteins. [PDF]

Int J Mol Sci
Pennacchietti V, Di Felice M, Toso J, Caldarelli L, Ventura ES, Malagrinò F, Toto A, Gianni S.   +7 more
europepmc   +1 more source